A phase 3 randomized trial found that Mim8 prophylaxis significantly reduced bleeding rates compared with on-demand therapy and clotting factor prophylaxis in patients with hemophilia A with or without...
The FDA has approved concizumab-mtci, a daily subcutaneous treatment to reduce bleeding for patients with hemophilia who have clotting factor inhibitors.
The FDA has approved a novel therapy for patients with hemophilia A or B without inhibitors. Clinical trials showed it significantly reduces bleeding episodes by targeting a new protein in the blood...
